301 related articles for article (PubMed ID: 26323606)
1. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Rudà R; Bosa C; Magistrello M; Franchino F; Pellerino A; Fiano V; Trevisan M; Cassoni P; Soffietti R
Neuro Oncol; 2016 Feb; 18(2):261-8. PubMed ID: 26323606
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Chamberlain MC; Johnston SK
Cancer; 2009 Oct; 115(20):4775-82. PubMed ID: 19569246
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for intracranial ependymoma in adults.
Gramatzki D; Roth P; Felsberg J; Hofer S; Rushing EJ; Hentschel B; Westphal M; Krex D; Simon M; Schnell O; Wick W; Reifenberger G; Weller M
BMC Cancer; 2016 Apr; 16():287. PubMed ID: 27108407
[TBL] [Abstract][Full Text] [Related]
5. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
6. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Komori K; Yanagisawa R; Miyairi Y; Sakashita K; Shiohara M; Fujihara I; Morita D; Nakamura T; Ogiso Y; Sano K; Shirahata M; Fukuoka K; Ichimura K; Shigeta H
Pediatr Blood Cancer; 2016 Jan; 63(1):152-5. PubMed ID: 26305586
[TBL] [Abstract][Full Text] [Related]
8. A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Rehman S; Brock C; Newlands ES
Am J Clin Oncol; 2006 Feb; 29(1):106-7. PubMed ID: 16462515
[No Abstract] [Full Text] [Related]
9. Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review.
Fujiwara Y; Manabe H; Izumi B; Shima T; Adachi N
Eur Spine J; 2018 Jul; 27(Suppl 3):421-425. PubMed ID: 29270703
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Chamberlain MC; Tsao-Wei DD; Groshen S
Cancer; 2006 Jan; 106(1):172-9. PubMed ID: 16323194
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Chamberlain MC
Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
[TBL] [Abstract][Full Text] [Related]
12. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T;
J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671
[TBL] [Abstract][Full Text] [Related]
14. Salvage temozolomide for prior temozolomide responders.
Franceschi E; Omuro AM; Lassman AB; Demopoulos A; Nolan C; Abrey LE
Cancer; 2005 Dec; 104(11):2473-6. PubMed ID: 16270316
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Gilbert MR; Yuan Y; Wu J; Mendoza T; Vera E; Omuro A; Lieberman F; Robins HI; Gerstner ER; Wu J; Wen PY; Mikkelsen T; Aldape K; Armstrong TS
Neuro Oncol; 2021 Mar; 23(3):468-477. PubMed ID: 33085768
[TBL] [Abstract][Full Text] [Related]
16. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.
Lombardi G; Pambuku A; Bellu L; Della Puppa A; Rumanò L; Gardiman MP; Pomerri F; Zagonel V
Chemotherapy; 2013; 59(3):176-80. PubMed ID: 24192541
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
